Американское общество гирудотерапии

Heparin-Induced Thrombocytopenia After Mitral Valve Replacement

Case report published in Ochsner journal (2021)

Последнее обновление: June 18, 2026Рецензент: ASH Editorial Board
Research article — evidence reviewArticle reference
Evidence: Case reportКлинические исследованияTugulan C et al. · Ochsner journal, 2021

Abstract

Background: Heparin-induced thrombocytopenia (HIT) is a rare autoimmune reaction that involves a decrease in platelet count following heparin exposure and can be associated with life-threatening thrombosis. Because of their prolonged heparin exposure, patients undergoing cardiac surgery are at risk of HIT, with an incidence of 0.1% to 3%. Case Report: A 65-year-old male with severe mitral regurgitation and preoperative ejection fraction of 20% to 25% underwent mitral valve bioprosthetic replacement with coronary artery bypass graft surgery. Heparin anticoagulation was started on postoperative day (POD) 1. Respiratory failure resulted in prolonged mechanical ventilation and heparinization without the ability to initiate warfarin. While the patient was on heparin, his platelet count declined on POD 2 and then steadily increased to above the preoperative level on POD 7. On POD 10, the patient's platelet count dramatically decreased, and on POD 13 he developed acute common femoral artery occlusion necessitating embolectomy. Intraoperative transesophageal echocardiography revealed heavy thrombus burden across the mitral bioprosthesis. HIT was confirmed with a positive heparin-induced platelet antibody and serotonin release assay. Heparin was stopped and argatroban initiated. The patient underwent reoperative bioprosthetic mitral valve replacement on POD 18 using bivalirudin intraoperatively. Despite resolution of HIT, the patient developed sepsis and died on POD 59. Conclusion: The diagnosis of HIT is challenging in patients who undergo cardiopulmonary bypass. Platelet counts often decrease 40% to 60% during the first 72 hours postoperatively, and the frequency of nonspecific anti-platelet factor 4/heparin antibody formation is high. These findings can mask early signs of HIT and delay diagnosis.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeCase ReportsJournal Article

Резюме

Heparin-induced thrombocytopenia (HIT) is a rare autoimmune reaction that involves a decrease in platelet count following heparin exposure and can be associated with life-threatening thrombosis.

Почему это важно для гирудотерапии

This case report describes a 65-year-old male who developed heparin-induced thrombocytopenia (HIT) after mitral valve replacement surgery, confirmed by positive heparin-induced platelet antibodies and serotonin release assay, ultimately requiring reoperative valve replacement using bivalirudin anticoagulation. The case highlights the diagnostic challenges of HIT in cardiac surgery patients, where routine postoperative platelet count fluctuations and frequent nonspecific anti-PF4/heparin antibody formation can mask early signs of the condition. For ASH's domain, this report illustrates a clinical scenario where alternative anticoagulants must substitute for heparin — a pharmacological parallel to the anticoagulant principles underlying hirudotherapy, though leech-derived anticoagulants were not involved. The article does not involve leeches or leech-derived substances and has no direct hirudotherapy relevance. It is a single case report, limiting generalizability.

Цитирование

Heparin-Induced Thrombocytopenia After Mitral Valve Replacement

Tugulan C et al. · Ochsner journal, 2021

Связанный клинический контекст

Узнайте, как это исследование связано с клинической практикой

Добавлено в библиотеку ASH: May 27, 2026 · Последнее обновление сайта: June 18, 2026

Этот сайт предоставляет образовательную информацию и не является медицинской консультацией, диагнозом или рекомендацией по лечению. Гирудотерапия сопряжена с клинически значимыми рисками и должна проводиться только квалифицированными клиницистами в рамках институционально утверждённых протоколов. Разрешение FDA 510(k) для медицинских пиявок ограничено определёнными показаниями; обсуждения исследовательского и нелицензионного применения отмечены соответствующим образом. Для индивидуальных медицинских рекомендаций обратитесь к квалифицированному медицинскому специалисту.